Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program

R. Goldberg, M. Temprosa, J. Otvos, J. Brunzell, S. Marcovina, Kieren Mather, R. Arakaki, K. Watson, E. Horton, E. Barrett-Connor

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Context: Although intensive lifestyle change (ILS) and metformin reduce diabetes incidence in subjects with impaired glucose tolerance (IGT), their effects on lipoprotein subfractions have not been studied. Objective: The objective of the study was to characterize the effects of ILS and metformin vs placebo interventions on lipoprotein subfractions in the Diabetes Prevention Program. Design: This was a randomized clinical trial, testing the effects of ILS, metformin, and placebo on diabetes development in subjects with IGT. Participants: Selected individuals with IGT randomized in the Diabetes Prevention Program participated in the study. Interventions: Interventions included randomization to metformin 850 mg or placebo twice daily or ILS aimed at a 7% weight loss using a low-fat diet with increased physical activity. Main Outcome Measures: Lipoprotein subfraction size, density, and concentration measured by magnetic resonance and density gradient ultra centrifugation at baseline and 1 year were measured. Results: ILS decreased large and buoyant very low-density lipoprotein, small and dense low-density lipoprotein (LDL), and small high-density lipoprotein (HDL) and raised large HDL. Metformin modestly reduced small and dense LDL and raised small and large HDL. Change in insulin resistance largely accounted for the intervention-associated decreases in large very low-density lipoprotein, whereas changes in body mass index (BMI) and adiponectin were strongly associated with changes in LDL. Baseline and a change in adiponectin were related to change in large HDL, and BMI change associated with small HDL change. The effect of metformin to increase small HDL was in dependent of adiponectin, BMI, and insulin resistance. Conclusion: ILS and metformin treatment have favorable effects on lipoprotein subfractions that are primarily mediated by intervention-related changes in insulin resistance, BMI, and adiponectin. Interventions that slow the development of diabetes may also retard the progression of atherosclerosis.

Original languageEnglish
Pages (from-to)3989-3998
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Metformin
Medical problems
Lipoproteins
HDL Lipoproteins
Life Style
Adiponectin
Glucose Intolerance
Body Mass Index
LDL Lipoproteins
Insulin Resistance
VLDL Lipoproteins
Placebos
Insulin
Glucose
Therapeutics
Fat-Restricted Diet
Density Gradient Centrifugation
Magnetic resonance
Nutrition
Random Allocation

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program. / Goldberg, R.; Temprosa, M.; Otvos, J.; Brunzell, J.; Marcovina, S.; Mather, Kieren; Arakaki, R.; Watson, K.; Horton, E.; Barrett-Connor, E.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 10, 10.2013, p. 3989-3998.

Research output: Contribution to journalArticle

Goldberg, R, Temprosa, M, Otvos, J, Brunzell, J, Marcovina, S, Mather, K, Arakaki, R, Watson, K, Horton, E & Barrett-Connor, E 2013, 'Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program', Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 10, pp. 3989-3998. https://doi.org/10.1210/jc.2013-1452
Goldberg, R. ; Temprosa, M. ; Otvos, J. ; Brunzell, J. ; Marcovina, S. ; Mather, Kieren ; Arakaki, R. ; Watson, K. ; Horton, E. ; Barrett-Connor, E. / Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 10. pp. 3989-3998.
@article{767b3d10c87342a2b060460e1ab86579,
title = "Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program",
abstract = "Context: Although intensive lifestyle change (ILS) and metformin reduce diabetes incidence in subjects with impaired glucose tolerance (IGT), their effects on lipoprotein subfractions have not been studied. Objective: The objective of the study was to characterize the effects of ILS and metformin vs placebo interventions on lipoprotein subfractions in the Diabetes Prevention Program. Design: This was a randomized clinical trial, testing the effects of ILS, metformin, and placebo on diabetes development in subjects with IGT. Participants: Selected individuals with IGT randomized in the Diabetes Prevention Program participated in the study. Interventions: Interventions included randomization to metformin 850 mg or placebo twice daily or ILS aimed at a 7{\%} weight loss using a low-fat diet with increased physical activity. Main Outcome Measures: Lipoprotein subfraction size, density, and concentration measured by magnetic resonance and density gradient ultra centrifugation at baseline and 1 year were measured. Results: ILS decreased large and buoyant very low-density lipoprotein, small and dense low-density lipoprotein (LDL), and small high-density lipoprotein (HDL) and raised large HDL. Metformin modestly reduced small and dense LDL and raised small and large HDL. Change in insulin resistance largely accounted for the intervention-associated decreases in large very low-density lipoprotein, whereas changes in body mass index (BMI) and adiponectin were strongly associated with changes in LDL. Baseline and a change in adiponectin were related to change in large HDL, and BMI change associated with small HDL change. The effect of metformin to increase small HDL was in dependent of adiponectin, BMI, and insulin resistance. Conclusion: ILS and metformin treatment have favorable effects on lipoprotein subfractions that are primarily mediated by intervention-related changes in insulin resistance, BMI, and adiponectin. Interventions that slow the development of diabetes may also retard the progression of atherosclerosis.",
author = "R. Goldberg and M. Temprosa and J. Otvos and J. Brunzell and S. Marcovina and Kieren Mather and R. Arakaki and K. Watson and E. Horton and E. Barrett-Connor",
year = "2013",
month = "10",
doi = "10.1210/jc.2013-1452",
language = "English",
volume = "98",
pages = "3989--3998",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program

AU - Goldberg, R.

AU - Temprosa, M.

AU - Otvos, J.

AU - Brunzell, J.

AU - Marcovina, S.

AU - Mather, Kieren

AU - Arakaki, R.

AU - Watson, K.

AU - Horton, E.

AU - Barrett-Connor, E.

PY - 2013/10

Y1 - 2013/10

N2 - Context: Although intensive lifestyle change (ILS) and metformin reduce diabetes incidence in subjects with impaired glucose tolerance (IGT), their effects on lipoprotein subfractions have not been studied. Objective: The objective of the study was to characterize the effects of ILS and metformin vs placebo interventions on lipoprotein subfractions in the Diabetes Prevention Program. Design: This was a randomized clinical trial, testing the effects of ILS, metformin, and placebo on diabetes development in subjects with IGT. Participants: Selected individuals with IGT randomized in the Diabetes Prevention Program participated in the study. Interventions: Interventions included randomization to metformin 850 mg or placebo twice daily or ILS aimed at a 7% weight loss using a low-fat diet with increased physical activity. Main Outcome Measures: Lipoprotein subfraction size, density, and concentration measured by magnetic resonance and density gradient ultra centrifugation at baseline and 1 year were measured. Results: ILS decreased large and buoyant very low-density lipoprotein, small and dense low-density lipoprotein (LDL), and small high-density lipoprotein (HDL) and raised large HDL. Metformin modestly reduced small and dense LDL and raised small and large HDL. Change in insulin resistance largely accounted for the intervention-associated decreases in large very low-density lipoprotein, whereas changes in body mass index (BMI) and adiponectin were strongly associated with changes in LDL. Baseline and a change in adiponectin were related to change in large HDL, and BMI change associated with small HDL change. The effect of metformin to increase small HDL was in dependent of adiponectin, BMI, and insulin resistance. Conclusion: ILS and metformin treatment have favorable effects on lipoprotein subfractions that are primarily mediated by intervention-related changes in insulin resistance, BMI, and adiponectin. Interventions that slow the development of diabetes may also retard the progression of atherosclerosis.

AB - Context: Although intensive lifestyle change (ILS) and metformin reduce diabetes incidence in subjects with impaired glucose tolerance (IGT), their effects on lipoprotein subfractions have not been studied. Objective: The objective of the study was to characterize the effects of ILS and metformin vs placebo interventions on lipoprotein subfractions in the Diabetes Prevention Program. Design: This was a randomized clinical trial, testing the effects of ILS, metformin, and placebo on diabetes development in subjects with IGT. Participants: Selected individuals with IGT randomized in the Diabetes Prevention Program participated in the study. Interventions: Interventions included randomization to metformin 850 mg or placebo twice daily or ILS aimed at a 7% weight loss using a low-fat diet with increased physical activity. Main Outcome Measures: Lipoprotein subfraction size, density, and concentration measured by magnetic resonance and density gradient ultra centrifugation at baseline and 1 year were measured. Results: ILS decreased large and buoyant very low-density lipoprotein, small and dense low-density lipoprotein (LDL), and small high-density lipoprotein (HDL) and raised large HDL. Metformin modestly reduced small and dense LDL and raised small and large HDL. Change in insulin resistance largely accounted for the intervention-associated decreases in large very low-density lipoprotein, whereas changes in body mass index (BMI) and adiponectin were strongly associated with changes in LDL. Baseline and a change in adiponectin were related to change in large HDL, and BMI change associated with small HDL change. The effect of metformin to increase small HDL was in dependent of adiponectin, BMI, and insulin resistance. Conclusion: ILS and metformin treatment have favorable effects on lipoprotein subfractions that are primarily mediated by intervention-related changes in insulin resistance, BMI, and adiponectin. Interventions that slow the development of diabetes may also retard the progression of atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=84885220015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885220015&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-1452

DO - 10.1210/jc.2013-1452

M3 - Article

VL - 98

SP - 3989

EP - 3998

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -